Search research articles
Contact Us
Filters
Showing results (231-240 of 251) with videos related to
Page
of 26
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
Targeted Oncology
|
March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Annals of Hepato-Biliary-Pancreatic Surgery
|
April 28, 2024
Practice guidelines for managing extrahepatic biliary tract cancers
Hyung Sun Kim, Mee Joo Kang, Jingu Kang, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
The Oncologist
|
October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Federica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Oncology
|
January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index
Mara Persano, Margherita Rimini, Francesca Salani, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab
Chiara Pirrone, Umberto Malapelle, Francesco Pepe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 22, 2024
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 251) with videos related to
Sort By:
Page
of 26
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
Targeted Oncology
|
March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Annals of Hepato-Biliary-Pancreatic Surgery
|
April 28, 2024
Practice guidelines for managing extrahepatic biliary tract cancers
Hyung Sun Kim, Mee Joo Kang, Jingu Kang, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
The Oncologist
|
October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Federica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Oncology
|
January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index
Mara Persano, Margherita Rimini, Francesca Salani, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab
Chiara Pirrone, Umberto Malapelle, Francesco Pepe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 22, 2024
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Mara Persano, Margherita Rimini, Toshifumi Tada, et al.
Page
of 26